Article Text

other Versions

Download PDFPDF
Role of PRPS2 as a prognostic and therapeutic target in osteosarcoma
  1. Yanli Luo,
  2. Junqing Yuan,
  3. Jin Huang,
  4. Tingting Yang,
  5. Jun Zhou,
  6. Juan Tang,
  7. Min Liu,
  8. Jie Chen,
  9. Chunyan Chen,
  10. Wentao Huang,
  11. Huizhen Zhang
  1. Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
  1. Correspondence to Dr Huizhen Zhang, Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; huizhenzhang2015{at}163.com

Abstract

Aims Osteosarcoma (OS) is the most common primary malignant tumour of the bone. However, further improvement in survival has not been achieved due to a lack of well-validated prognostic markers and more effective therapeutic agents. Recently, the c-Myc–phosphoribosyl pyrophosphate synthetase 2 (PRPS2) pathway has been shown to promote nucleic acid metabolism and cancer cell proliferation in malignant melanoma; phosphorylated mammalian target of rapamycin (p-mTOR) has been upregulated and an effective therapeutic target in OS. However, the p-mTOR–PRPS2 pathway has not been evaluated in OS.

Methods In this study, the expression level of PRPS2, p-mTOR and marker of proliferation (MKI-67) was observed in a cohort of specimens (including 236 OS cases and 56 control samples) using immunohistochemistry, and the association between expression level and clinicopathological characteristics of patients with OS was analysed.

Results PRPS2 protein level, which is related to tumour proliferation, was higher in OS cells (p=0.003) than in fibrous dysplasia, and the higher PRPS2 protein level was associated with a higher tumour recurrence (p=0.001). In addition, our statistical analysis confirmed that PRPS2 is a novel, independent prognostic indicator of OS. Finally, we found that the expression of p-mTOR was associated with the poor prognosis of patients with OS (p<0.05).

Conclusions PRPS2 is an independent prognostic marker and a potential therapeutic target for OS.

  • metabolism
  • bone tumours
  • carcinoma
  • molecular pathology

Statistics from Altmetric.com

Footnotes

  • Handling editor Dhirendra Govender.

  • Contributors Review of the pathology was undertaken by histopathologists HZ, WH, JH and JZ. YL provided many ideas in guiding the experiments and analysed the data. Samples were collected by JY. Survival information was obtained through telephone calls by JH and CC. Immunohistochemistry was completed by ML, JC, JT and TY. The manuscript was written by YL. The article was reviewed by HZ, YL, JH and WH.

  • Funding This work was supported by the Interdisciplinary Program of Shanghai Jiao Tong University (grant number YG2015QN12), Shanghai Science and Technology Development fund (grant number 19MC1911000) and the National Natural Science Foundation (grant number 81602099).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval This study was conducted ethically with preapproval from the ethics committee for human studies at Shanghai Jiaotong University and according to the Declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplemental information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles